PortalPublikationenAdenocarcinoma of the Bladder: Assessment of Survival Advant...

Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer

Standard

Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer. / Tappero, Stefano; Barletta, Francesco; Piccinelli, Mattia Luca; Cano Garcia, Cristina; Incesu, Reha-Baris; Morra, Simone; Scheipner, Lukas; Tian, Zhe; Parodi, Stefano; Dell'Oglio, Paolo; Briganti, Alberto; de Cobelli, Ottavio; Chun, Felix K H; Graefen, Markus; Mirone, Vincenzo; Ahyai, Sascha; Saad, Fred; Shariat, Shahrokh F; Suardi, Nazareno; Borghesi, Marco; Terrone, Carlo; Karakiewicz, Pierre I.

in: UROL ONCOL-SEMIN ORI, Jahrgang 41, Nr. 7, 07.2023, S. 326.e9-326.e16.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Tappero, S, Barletta, F, Piccinelli, ML, Cano Garcia, C, Incesu, R-B, Morra, S, Scheipner, L, Tian, Z, Parodi, S, Dell'Oglio, P, Briganti, A, de Cobelli, O, Chun, FKH, Graefen, M, Mirone, V, Ahyai, S, Saad, F, Shariat, SF, Suardi, N, Borghesi, M, Terrone, C & Karakiewicz, PI 2023, 'Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer', UROL ONCOL-SEMIN ORI, Jg. 41, Nr. 7, S. 326.e9-326.e16. https://doi.org/10.1016/j.urolonc.2023.01.015

APA

Tappero, S., Barletta, F., Piccinelli, M. L., Cano Garcia, C., Incesu, R-B., Morra, S., Scheipner, L., Tian, Z., Parodi, S., Dell'Oglio, P., Briganti, A., de Cobelli, O., Chun, F. K. H., Graefen, M., Mirone, V., Ahyai, S., Saad, F., Shariat, S. F., Suardi, N., ... Karakiewicz, P. I. (2023). Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer. UROL ONCOL-SEMIN ORI, 41(7), 326.e9-326.e16. https://doi.org/10.1016/j.urolonc.2023.01.015

Vancouver

Tappero S, Barletta F, Piccinelli ML, Cano Garcia C, Incesu R-B, Morra S et al. Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer. UROL ONCOL-SEMIN ORI. 2023 Jul;41(7):326.e9-326.e16. https://doi.org/10.1016/j.urolonc.2023.01.015

Bibtex

@article{c60242b5666441ee984cd4050bbee63f,
title = "Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer",
abstract = "PURPOSE: To evaluate the association between radical cystectomy (RC) and cancer-specific mortality (CSM) in patients diagnosed with adenocarcinoma of the bladder (ACB). Moreover, to directly compare the survival advantage of RC between ACB vs. urothelial bladder cancer (UBC).MATERIALS AND METHODS: Non-metastatic muscle-invasive ACB and UBC patients were identified within Surveillance, Epidemiology, and End Results database (SEER 2000-2018). All analyses were stratified between RC vs. no-RC, in either organ-confined (OC: T2N0M0) or non-organ-confined (NOC: T3-4N0M0 or TanyN1-3M0) stages. Propensity score matching (PSM), cumulative incidence plots, competing risks regression (CRR) analyses, and 3 months' landmark analyses were performed.RESULTS: Overall, 1,005 ACB and 47,741 UBC patients were identified, of whom 475 (47%) and 19,499 (41%) were treated with RC, respectively. After PSM, comparison between RC vs. no-RC applied to 127 vs. 127 OC-ACB, 7,611 vs. 7,611 OC-UBC, 143 vs. 143 NOC-ACB, and 4,664 vs. 4,664 NOC-UBC patients. 36-month CSM rates in RC vs. no-RC patients were 14 vs. 44% in OC-ACB, 18 vs. 39% in OC-UBC, 49 vs. 66% in NOC-ACB, and 44 vs. 56% in NOC-UBC patients. In CRR analyses, the effect of RC on CSM yielded a hazard ratio of 0.37 in OC-ACB, of 0.45 in OC-UBC, of 0.65 in NOC-ACB and of 0.68 in NOC-UBC patients (all P values<0.001). Landmark analyses virtually perfectly replicated the results.CONCLUSIONS: In ACB, regardless of stage, RC is associated with lower CSM. The magnitude of this survival advantage was greater in ACB than in UBC, even after control for immortal time bias.",
keywords = "Humans, Urinary Bladder/surgery, Cystectomy/methods, SEER Program, Urinary Bladder Neoplasms/pathology, Carcinoma, Transitional Cell/pathology, Adenocarcinoma, Retrospective Studies",
author = "Stefano Tappero and Francesco Barletta and Piccinelli, {Mattia Luca} and {Cano Garcia}, Cristina and Reha-Baris Incesu and Simone Morra and Lukas Scheipner and Zhe Tian and Stefano Parodi and Paolo Dell'Oglio and Alberto Briganti and {de Cobelli}, Ottavio and Chun, {Felix K H} and Markus Graefen and Vincenzo Mirone and Sascha Ahyai and Fred Saad and Shariat, {Shahrokh F} and Nazareno Suardi and Marco Borghesi and Carlo Terrone and Karakiewicz, {Pierre I}",
note = "Copyright {\textcopyright} 2023 Elsevier Inc. All rights reserved.",
year = "2023",
month = jul,
doi = "10.1016/j.urolonc.2023.01.015",
language = "English",
volume = "41",
pages = "326.e9--326.e16",
journal = "UROL ONCOL-SEMIN ORI",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "7",

}

RIS

TY - JOUR

T1 - Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer

AU - Tappero, Stefano

AU - Barletta, Francesco

AU - Piccinelli, Mattia Luca

AU - Cano Garcia, Cristina

AU - Incesu, Reha-Baris

AU - Morra, Simone

AU - Scheipner, Lukas

AU - Tian, Zhe

AU - Parodi, Stefano

AU - Dell'Oglio, Paolo

AU - Briganti, Alberto

AU - de Cobelli, Ottavio

AU - Chun, Felix K H

AU - Graefen, Markus

AU - Mirone, Vincenzo

AU - Ahyai, Sascha

AU - Saad, Fred

AU - Shariat, Shahrokh F

AU - Suardi, Nazareno

AU - Borghesi, Marco

AU - Terrone, Carlo

AU - Karakiewicz, Pierre I

N1 - Copyright © 2023 Elsevier Inc. All rights reserved.

PY - 2023/7

Y1 - 2023/7

N2 - PURPOSE: To evaluate the association between radical cystectomy (RC) and cancer-specific mortality (CSM) in patients diagnosed with adenocarcinoma of the bladder (ACB). Moreover, to directly compare the survival advantage of RC between ACB vs. urothelial bladder cancer (UBC).MATERIALS AND METHODS: Non-metastatic muscle-invasive ACB and UBC patients were identified within Surveillance, Epidemiology, and End Results database (SEER 2000-2018). All analyses were stratified between RC vs. no-RC, in either organ-confined (OC: T2N0M0) or non-organ-confined (NOC: T3-4N0M0 or TanyN1-3M0) stages. Propensity score matching (PSM), cumulative incidence plots, competing risks regression (CRR) analyses, and 3 months' landmark analyses were performed.RESULTS: Overall, 1,005 ACB and 47,741 UBC patients were identified, of whom 475 (47%) and 19,499 (41%) were treated with RC, respectively. After PSM, comparison between RC vs. no-RC applied to 127 vs. 127 OC-ACB, 7,611 vs. 7,611 OC-UBC, 143 vs. 143 NOC-ACB, and 4,664 vs. 4,664 NOC-UBC patients. 36-month CSM rates in RC vs. no-RC patients were 14 vs. 44% in OC-ACB, 18 vs. 39% in OC-UBC, 49 vs. 66% in NOC-ACB, and 44 vs. 56% in NOC-UBC patients. In CRR analyses, the effect of RC on CSM yielded a hazard ratio of 0.37 in OC-ACB, of 0.45 in OC-UBC, of 0.65 in NOC-ACB and of 0.68 in NOC-UBC patients (all P values<0.001). Landmark analyses virtually perfectly replicated the results.CONCLUSIONS: In ACB, regardless of stage, RC is associated with lower CSM. The magnitude of this survival advantage was greater in ACB than in UBC, even after control for immortal time bias.

AB - PURPOSE: To evaluate the association between radical cystectomy (RC) and cancer-specific mortality (CSM) in patients diagnosed with adenocarcinoma of the bladder (ACB). Moreover, to directly compare the survival advantage of RC between ACB vs. urothelial bladder cancer (UBC).MATERIALS AND METHODS: Non-metastatic muscle-invasive ACB and UBC patients were identified within Surveillance, Epidemiology, and End Results database (SEER 2000-2018). All analyses were stratified between RC vs. no-RC, in either organ-confined (OC: T2N0M0) or non-organ-confined (NOC: T3-4N0M0 or TanyN1-3M0) stages. Propensity score matching (PSM), cumulative incidence plots, competing risks regression (CRR) analyses, and 3 months' landmark analyses were performed.RESULTS: Overall, 1,005 ACB and 47,741 UBC patients were identified, of whom 475 (47%) and 19,499 (41%) were treated with RC, respectively. After PSM, comparison between RC vs. no-RC applied to 127 vs. 127 OC-ACB, 7,611 vs. 7,611 OC-UBC, 143 vs. 143 NOC-ACB, and 4,664 vs. 4,664 NOC-UBC patients. 36-month CSM rates in RC vs. no-RC patients were 14 vs. 44% in OC-ACB, 18 vs. 39% in OC-UBC, 49 vs. 66% in NOC-ACB, and 44 vs. 56% in NOC-UBC patients. In CRR analyses, the effect of RC on CSM yielded a hazard ratio of 0.37 in OC-ACB, of 0.45 in OC-UBC, of 0.65 in NOC-ACB and of 0.68 in NOC-UBC patients (all P values<0.001). Landmark analyses virtually perfectly replicated the results.CONCLUSIONS: In ACB, regardless of stage, RC is associated with lower CSM. The magnitude of this survival advantage was greater in ACB than in UBC, even after control for immortal time bias.

KW - Humans

KW - Urinary Bladder/surgery

KW - Cystectomy/methods

KW - SEER Program

KW - Urinary Bladder Neoplasms/pathology

KW - Carcinoma, Transitional Cell/pathology

KW - Adenocarcinoma

KW - Retrospective Studies

U2 - 10.1016/j.urolonc.2023.01.015

DO - 10.1016/j.urolonc.2023.01.015

M3 - SCORING: Journal article

C2 - 36882338

VL - 41

SP - 326.e9-326.e16

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 7

ER -